{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:48:12Z","timestamp":1794361692205,"version":"4.9.0"},"reference-count":26,"publisher":"American Association for Cancer Research (AACR)","issue":"20","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Certain solid tumors metastasize to bone and cause osteolysis and abnormal new bone formation. The respective phenotypes of dysregulated bone destruction and bone formation represent two ends of a spectrum, and most patients will have evidence of both. The mechanisms responsible for tumor growth in bone are complex and involve tumor stimulation of the osteoclast and the osteoblast as well as the response of the bone microenvironment. Furthermore, factors that increase bone resorption, independent of tumor, such as sex steroid deficiency, may contribute to this vicious cycle of tumor growth in bone. This article discusses mechanisms and therapeutic implications of osteolytic and osteoblastic bone metastases.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-06-1007","type":"journal-article","created":{"date-parts":[[2006,10,24]],"date-time":"2006-10-24T17:41:28Z","timestamp":1161711688000},"page":"6213s-6216s","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":452,"title":["Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases"],"prefix":"10.1158","volume":"12","author":[{"given":"Theresa A.","family":"Guise","sequence":"first","affiliation":[{"name":"1University of Virginia, Charlottesville, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid S.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"1University of Virginia, Charlottesville, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Clines","sequence":"additional","affiliation":[{"name":"1University of Virginia, Charlottesville, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Stebbins","sequence":"additional","affiliation":[{"name":"2Scios, Inc., Fremont, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren H.","family":"Wong","sequence":"additional","affiliation":[{"name":"2Scios, Inc., Fremont, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Higgins","sequence":"additional","affiliation":[{"name":"2Scios, Inc., Fremont, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vessella","sequence":"additional","affiliation":[{"name":"3University of Washington, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Corey","sequence":"additional","affiliation":[{"name":"2Scios, Inc., Fremont, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Padalecki","sequence":"additional","affiliation":[{"name":"1University of Virginia, Charlottesville, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Suva","sequence":"additional","affiliation":[{"name":"4University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Chirgwin","sequence":"additional","affiliation":[{"name":"1University of Virginia, Charlottesville, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,10,24]]},"reference":[{"key":"2022061105004122500_B1","doi-asserted-by":"crossref","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med\u20082004;350:1655\u201364.","DOI":"10.1056\/NEJMra030831"},{"key":"2022061105004122500_B2","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer\u20082002;2:584\u201393.","DOI":"10.1038\/nrc867"},{"key":"2022061105004122500_B3","unstructured":"Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis\u20082003;20:171\u201380."},{"key":"2022061105004122500_B4","doi-asserted-by":"crossref","unstructured":"Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-\u03baB ligand pathway. Cancer Res\u20082005;65:11001\u20139.","DOI":"10.1158\/0008-5472.CAN-05-2630"},{"key":"2022061105004122500_B5","doi-asserted-by":"crossref","unstructured":"Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-\u03b2 stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem\u20082002;277:24571\u20138.","DOI":"10.1074\/jbc.M202561200"},{"key":"2022061105004122500_B6","doi-asserted-by":"crossref","unstructured":"Yin JJ, Selander K, Chirgwin JM, et al. TGF-\u03b2 signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest\u20081999;103:197\u2013206.","DOI":"10.1172\/JCI3523"},{"key":"2022061105004122500_B7","doi-asserted-by":"crossref","unstructured":"Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest\u20081996;98:1544\u20139.","DOI":"10.1172\/JCI118947"},{"key":"2022061105004122500_B8","doi-asserted-by":"crossref","unstructured":"Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell\u20082003;3:537\u201349.","DOI":"10.1016\/S1535-6108(03)00132-6"},{"key":"2022061105004122500_B9","doi-asserted-by":"crossref","unstructured":"Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A\u20082005;102:13909\u201314.","DOI":"10.1073\/pnas.0506517102"},{"key":"2022061105004122500_B10","doi-asserted-by":"crossref","unstructured":"Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-\u03b2 (TGF-\u03b2)-binding protein-1 by osteoclasts: a cellular mechanism for release of TGF-\u03b2 from bone matrix. J Biol Chem\u20082002;277:21352\u201360.","DOI":"10.1074\/jbc.M111663200"},{"key":"2022061105004122500_B11","doi-asserted-by":"crossref","unstructured":"Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst\u20082005;97:59\u201369.","DOI":"10.1093\/jnci\/dji002"},{"key":"2022061105004122500_B12","doi-asserted-by":"crossref","unstructured":"Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol\u20082005;23:4925\u201335.","DOI":"10.1200\/JCO.2005.06.091"},{"key":"2022061105004122500_B13","doi-asserted-by":"crossref","unstructured":"Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol\u20082002;168:1005\u20137.","DOI":"10.1016\/S0022-5347(05)64561-2"},{"key":"2022061105004122500_B14","doi-asserted-by":"crossref","unstructured":"Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept\u20082003;112:175\u201383.","DOI":"10.1016\/S0167-0115(03)00037-5"},{"key":"2022061105004122500_B15","doi-asserted-by":"crossref","unstructured":"Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer\u20082003;3:110\u20136.","DOI":"10.1038\/nrc990"},{"key":"2022061105004122500_B16","doi-asserted-by":"crossref","unstructured":"Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A\u20082003;100:10954\u20139.","DOI":"10.1073\/pnas.1830978100"},{"key":"2022061105004122500_B17","doi-asserted-by":"crossref","unstructured":"Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med\u20081995;1:944\u20139.","DOI":"10.1038\/nm0995-944"},{"key":"2022061105004122500_B18","doi-asserted-by":"crossref","unstructured":"Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol\u20082003;21:679\u201389.","DOI":"10.1200\/JCO.2003.04.176"},{"key":"2022061105004122500_B19","unstructured":"Mohammad KS, Wang Z, Martinez A, et al. Adrenomedullin is made by prostate cancers and increases both osteolytic and osteoblastic bone metastases. J Bone Miner Res\u20082004;19:S25."},{"key":"2022061105004122500_B20","unstructured":"Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res\u20082002;62:917\u201323."},{"key":"2022061105004122500_B21","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med\u20082003;349:2483\u201394.","DOI":"10.1056\/NEJMoa030847"},{"key":"2022061105004122500_B22","unstructured":"Clines GA, Mohaddad KS, Wessner LL, Chirgwin JM, Guise TA. Endothelin-1 stimulates bone formation by regulating osteoblast secretion of the paracrine regulators IL-6, Cyr61, CTGF, and Dkk1. J Bone Miner Res\u20082005;20:S249."},{"key":"2022061105004122500_B23","doi-asserted-by":"crossref","unstructured":"Schluter KD, Katzer C, Piper HM. A N-terminal PTHrP peptide fragment void of a PTH\/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br J Pharmacol\u20082001;132:427\u201332.","DOI":"10.1038\/sj.bjp.0703830"},{"key":"2022061105004122500_B24","doi-asserted-by":"crossref","unstructured":"Saad F, Gleason DM, Murray R, et al; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst\u20082004;96:879\u201382.","DOI":"10.1093\/jnci\/djh141"},{"key":"2022061105004122500_B25","doi-asserted-by":"crossref","unstructured":"Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol\u20082005;23:7897\u2013903.","DOI":"10.1200\/JCO.2004.00.6908"},{"key":"2022061105004122500_B26","doi-asserted-by":"crossref","unstructured":"Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med\u20082001;345:948\u201355.","DOI":"10.1056\/NEJMoa010845"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/20\/6213s\/1966019\/6213s.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/20\/6213s\/1966019\/6213s.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T19:36:44Z","timestamp":1654976204000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/12\/20\/6213s\/191631\/Basic-Mechanisms-Responsible-for-Osteolytic-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,15]]},"references-count":26,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2006,10,24]]},"published-print":{"date-parts":[[2006,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-1007","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,15]]}}}